BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. On January 29, 2026, BioMarin Pharmaceutical Inc. priced a private offering of $...

BioMarin Secures Major Debt Financing for Amicus Acquisition

In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $110.00. Kasi...

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cormedix (CRMD – Research Report), BioMarin Pharma...

Current Quarter	$0.06	Next Quarter	$1.09
Current Year	$2.28	Next Year	$4.53
QoQ Growth	+1716.7%	YoY Growth	+98.7%
3Y EPS CAGR	+1.0%	Target Price	$90.96
Consensus	Buy	Upside	+57.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMRN	$57.95	+2.49%	1.86M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMRN	$57.95	+2.5%	1.86M
3
4
5
6

BMRN

BMRN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get BioMarin Pharmaceutical Inc. Data in Excel

Get BioMarin Pharmaceutical Inc. Data in Excel